Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2001

View Archived Issues

Sterix raises funds for R&D programs

Human growth hormone peptide analogue under active development for obesity

Copper/zinc chelator may address underlying cause of Alzheimer's disease

AstraZeneca selects tradename for investigational anticoagulant

Mechanism of blood pressure-lowering effects of PPARgamma agonists studied using GW-1929

BioMarin files application to conduct human trials with topical Vibriolysin

Amgen launches ARANESP in the E.U.

Beneficial effects of insulin sensitizer on lipoprotein abnormalities in db/db mice

Ligand and TAP establish R&D alliance for SARMs

EntreMed and NEI study Panzem in age-related macular degeneration

Efficacy and safety of COL-1621 demonstrated in men with testosterone deficiency

Zycos and Aventis Pasteur extend drug discovery alliance

Medarex and Epicyte to codevelop therapeutic antibodies

New GH receptor antagonist may have a role in the management of colon cancer

Phase I/II trial begins for malignant melanoma vaccine

NicOx and Biolipox to codevelop NO-releasing respiratory therapies

New, orally active PTP1B inhibitor lowers plasma glucose and insulin levels in ob/ob mice

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

International Psoriasis Symposium selected by MedImmune to present phase I results for MEDI-507

Profile of novel SERM indicates potential in both osteoporosis and endometriosis

Inhibitors of proteases such as cathepsin K and methods of use

Oligobenzimidazoles discovered by Aventis to be useful for DNA transfection

Orally active antifungal agents patented by Toagosei

Novel antiallergic agents in the Taisho pipeline

Chemokine antagonists claimed for wide series of conditions in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...